Keywords: Merck & Co, First-quarter 2012 financial results, Patent dispute, Mylan, Zetia, Vytorin, USA

Merck & Co 1st-qtr earnings just beat expectations; wins Mylan patent dispute

Article | 30 April 2012

Print This

US drug giant Merck & Co sales that global sales in the first-quarter of 2012 increased 1% to $11.7 billion, shy of analysts& ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in